The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases

Zilli, Thomas; Dirix, Piet; Heikkilä, Reino; Liefhooghe, Nick; Siva, Shankar; Gomez-Iturriaga, Alfonso; Everaerts, Wouter; Otte, François; Shelan, Mohamed; Mercier, Carole; Achard, Verane; Thon, Kristian; Stellamans, Karin; Moon, Daniel; Conde-Moreno, Antonio; Papachristofilou, Alexandros; Scorsetti, Marta; Gückenberger, Matthias; Ameye, Filip; Zapatero, Almudena; Van De Voorde, Lien; López Campos, Fernando; Couñago, Felipe; Jaccard, Maud; Spiessens, An; Werner, Isabelle; Vanhoutte, Frederik; Goetghebeur, Els; Reynders, Dries; Ost, Piet

doi:10.1016/j.euf.2020.12.010

Scientific article

English

The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases

Published inEuropean urology focus, vol. 7, no. 2, p. 241-244

Publication date2021-03

First online date2020-12-29

Abstract

Optimal local treatment for nodal oligorecurrent prostate cancer is unknown. The randomized phase 2 PEACE V-STORM trial will explore the best treatment approach in this setting. Early results on the acute toxicity profile are projected to be published in quarter 3, 2021.

Trial registration: ClinicalTrials.gov NCT03569241.

Keywords

Humans
Male
Prostatic Neoplasms / therapy
Salvage Therapy

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale

Citation (ISO format)

ZILLI, Thomas et al. The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. In: European urology focus, 2021, vol. 7, n° 2, p. 241–244. doi: 10.1016/j.euf.2020.12.010